RNAble
Modulating RNA Epitranscriptomics
StartupRNAble is a Ness Ziona-based startup in the Health Tech & Life Sciences sector, established in 2021. Modulating RNA Epitranscriptomics. RNAble was founded by Rotem Karni. Key investors include Integra Holdings, RMGLOBAL Healthcare Fund Management. The company has 1-10 employees. Core technologies: Biologicals, Genes.
The company follows a B2B business model. Product stage: Customer Development.
- StageSeed
- ProductCustomer Development
- ModelB2B
- Employees1-10
- HQNess Ziona
- Last RoundUndisclosed
- Integra HoldingsLead
- RMGLOBAL Healthcare Fund Management
Rotem KarniCo-Founder & Advisor
What does RNAble do?
RNAble is developing novel compounds that alter RNA stability through modulation of RNA epitranscriptomics for the treatment of specific cancers and rare genetic diseases with nonsense mutations. RNA transcripts undergo modifications that are recognized by specific RNA-binding proteins dictating their stability. Professor Rotem Karni, RNAble inventor, discovered that targeting components of the RNA epitranscriptomic machinery with small molecules resulted in the stabilization of several RNAs, including unstable nonsense mutated transcripts which are degraded by the nonsense-mediated decay machinery. This discovery opens the possibility of restoring the expression of mutated genes essential to rare diseases and suppressing the growth of specific cancers.
Who founded RNAble?
RNAble was founded in 2021 by Rotem Karni (Co-Founder & Advisor).
What sector is RNAble in?
RNAble operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Healthcare, Laboratories, Providers, Life Sciences, Biotechnology.
Where is RNAble located?
RNAble is based in Park Hamada Ilan Ramon St 2, Ness Ziona, Israel.